Myriad Genetics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Samraat S Raha
- Full Time Employees
- 2,700
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 322 North 2200 West Salt Lake City UT United States of America 84116
- IPO Date
- Oct 6, 1995
- CIK
- 0000899923
- Website
- myriad.com
- Similar Companies
- Business
- Myriad Genetics, Inc. (MYGN) operates as a leading molecular diagnostic testing and precision medicine company focused on hereditary cancer, reproductive health, oncology, urology, and mental health genetic testing; its core products include the myRisk Hereditary Cancer Test assessing risk for 11 major cancers across 63 genes, Prequel Prenatal Screen for chromosomal abnormalities like trisomies 21, 18, and 13, Foresight Carrier Screen for over 270 inherited conditions, GeneSight Psychotropic Test covering 61 medications for depression, anxiety, and ADHD, and Precise Oncology solutions such as molecular residual disease testing. Founded in 1991 and headquartered in Salt Lake City, Utah, the company employs proprietary technologies to analyze biological samples like blood or saliva, providing physicians and patients with actionable insights for disease risk prediction, treatment guidance, and progression assessment across the United States and internationally. Recent developments include a September 2025 strategic collaboration with SOPHiA GENETICS to develop companion diagnostics for liquid biopsy-based therapy selection, partnerships with GlaxoSmithKline for HRD testing in ovarian cancer, QIAGEN for distributable HRD tests, National Cancer Center Hospital East in Japan for molecular residual disease studies, PATHOMIQ for AI-enabled prostate cancer testing, and Clairity with MagView for an integrated AI-genetic risk platform in breast health; additionally, the company expanded its MyRisk panel, launched FirstGene combined prenatal screening, secured a $200 million senior secured term loan from OrbiMed in 2025 to support growth, and reported oncology volume increases alongside Q3 2025 financial results emphasizing product launches and commercial investments.
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences